We are pleased to announce the launch of Rhinosectan® in its first market, Spain.
Rhinosectan® is based on Xyloglucan, a mucomimetic agent that forms a protective barrier over the nasal epithelial mucosa, and it is specifically formulated to control and treat the symptoms of rhinitis and rhinosinusitis from different aetiologies, especially those of allergic origin.
The product is commercialized under the brand Rinonet/Rhinosectan®, is distributed by Laboratórios SALVAT S.A. and has been available as 15 ml solution for intranasal application in pharmacies across Spain since May.
Rhinosectan® is a class I medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (Noventure SL)
In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.